CERo Therapeutics enters amended convertible note for $1.4M; conversion price floor $0.05, 10% interest

CERO THERAPEUTICS HOLDINGS, INC.

Amended and restated promissory note with SRX Health Solutions for up to $1,413,600; $663,600 funded on June 23, 2026, on top of $750,000 from May 28 note.
Note bears 10% annual interest, matures May 28, 2027; convertible into common stock at the lesser of $0.05 or 80% of avg of 5 lowest intraday prices in prior 20 days.
Conversion subject to 4.99% beneficial ownership limitation; Company to file resale registration statement for shares issuable upon conversion.
Issuance exempt from registration under Section 4(a)(2) and Rule 506(b); Note and underlying shares unregistered.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.